A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living ...

Imdelltra significantly improves survival in SCLC patients post-platinum chemotherapy, meeting primary endpoints in the DeLLphi-304 trial. As a BiTE immunotherapy, Imdelltra enhances T cell-cancer ...

Despite a significant 48.8% objective response rate and breakthrough therapy status, this regulatory shift reverses years of ...

A recent study has analyzed the relationship between different air pollutants and the main subtypes of lung cancer.

Clinical predictors of response to immunotherapy in patients with extensive-stage small cell lung cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...

Imdelltra demonstrated superior overall survival and progression-free survival compared to standard chemotherapy in ES-SCLC patients post-platinum-based treatment. The DeLLphi-304 trial showed a ...

Yes, lung cancer can be curable — if it’s found early and responds well to treatment. Thanks to recent therapy advances, the lung cancer mortality rate has declined and survival rates have improved.

When lung cancer treatment stops working, what happens next? New research reveals the answer may depend on how the cancer grows.

Medicaid expansion under the ACA improved long-term survival for younger adults with operable lung cancer, despite no earlier stage diagnosis. States adopting Medicaid expansion saw improved survival ...